A prognostic scoring system that is cheap, efficient and reliable can predict how patients with relapsed and/or metastatic head and neck cancer will respond to immunotherapy, new research has shown.

The drug is the only immuno-oncology drug approved by various regulatory authorities around the world for the treatment of ...

COMEDIAN Rhod Gilbert has opened up after being hit by a heartbreaking double tragedy just months after his battle with stage ...

News on Telangana Today, Metastatic nasopharyngeal carcinoma (RM-NPC) latest news, Metastatic nasopharyngeal carcinoma (RM-NPC) news, | Telangana Today ...

Dr Reddy's Laboratories will be in the spotlight on Friday following the launch of toripalimab, an immune oncology drug ...

Nasopharyngeal carcinoma (NPC) is a rare, aggressive form of head and neck cancer that originates in the nasopharynx, the ...

Dr Reddy's Laboratories on Thursday said it has launched Toripalimab, a drug for the treatment of recurrent or metastatic ...

Dr. Reddy's Laboratories has announced the launch of Toripalimab in India. This drug is designed to treat adults suffering ...

Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or ...

Dr. Reddy's launches immuno-oncology drug Toripalimab in India for nasopharyngeal carcinoma, expanding access to innovative treatment.

Compared to normal tissues, where the expression of ULBP2/5/6 protein is restricted, in non-small-cell lung cancer (NSCLC), head and neck cancer and squamous urothelial carcinoma, the levels of ...

In 2023, Dr Reddy's signed a licensing and commercialisation agreement with Shanghai Junshi Biosciences for Toripalimab ...